PMID: 787618Aug 1, 1976Paper

The effect of uremia and transplantation on lymphocyte subpopulations

Kidney International
L J QuadracciM Krzymanski


The in vitro immune response of uremic and transplanted patients was studied by determining lymphocyte surface and functional markers. Because of lymphopenia, the absolute number of T and B cells are diminished in uremia and transplantation. The uremic state had a profound effect of T cell mitogenic response, while the relative number (%) of T cells was not reduced. B cell responses and relative numbers were significantly diminished. The early posttransplant period was associated with a significant reduction in both T and B cell response and relative numbers. All indexes returned toward normal late in the posttransplant course with reduction of immunosuppression and cessation of the uremic state. Horse anti-human lymphocyte globulin treatment caused a significant reduction in T cells and an increase in B cells. Prednisone therapy did not appear to influence the relative number of the lymphocyte subpopulation but did reduce the mitogenic responses. Changes in surface or functional markers did not prove useful in predicting rejection episodes in transplanted patients.


Jan 1, 1972·Transplantation Reviews·J AnderssonG Möller
Jul 31, 1971·British Medical Journal·A MunroC S Ogg
Mar 22, 1957·Annals of the New York Academy of Sciences·G J DAMMINJ E MURRAY

❮ Previous
Next ❯


Jul 1, 1989·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·R DrachmanA Drukker
Jan 1, 1980·International Urology and Nephrology·L NémethA Hámori
Aug 3, 2011·International Urology and Nephrology·Funda Sari, Hulya Taskapan
Nov 1, 1983·The American Journal of Medicine·K RaskaL Homer
Nov 1, 1988·Cancer Genetics and Cytogenetics·K CengizA A Sandberg
Jan 1, 1990·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·L MorraG Bessone
Jun 1, 1979·British Journal of Haematology·M Mansell, A J Grimes
May 16, 2008·Journal of the American Society of Nephrology : JASN·Nicolle Helena Renier LitjensMichiel Gerardus Henricus Betjes
Jan 1, 1981·Clinical and Experimental Dialysis and Apheresis·W E HoyR B Freeman
Jan 1, 1978·Journal of Dialysis·W E HoyR B Freeman
Feb 13, 2001·Kidney International. Supplement·J JankowskiH Schlüter
Jun 1, 1986·Kidney International·P KurzK H Meyer zum Büschenfelde
Oct 1, 1983·The American Journal of Medicine·M C RuddyK H Stenzel
Jan 1, 1980·Scandinavian Journal of Immunology·O Ringdén
Nov 1, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Nicolle H R LitjensMichiel G H Betjes
Jan 1, 1976·Immunological Communications·O RingdénE Möller
Feb 16, 2016·Transplant Infectious Disease : an Official Journal of the Transplantation Society·F LeoneR Bonofiglio
Nov 1, 1980·The Veterinary Clinics of North America. Small Animal Practice·C A OsborneG E Lees
Apr 27, 2007·European Journal of Immunology·Odelia KatzDrorit Neumann
May 1, 1981·Clinical Endocrinology·D J HandelsmanJ R Turtle
Dec 17, 2004·Renal Failure·Ioannis GriveasG Sakellariou
May 9, 2019·Canadian Journal of Kidney Health and Disease·Caroline LamarcheThomas Kitzler
Apr 1, 1983·The Journal of the American Paraplegia Society·M K MirahmadiN Penera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.